enGene Therapeutics

enGene Therapeutics

Founded in the late 1990s and previously private for over two decades, enGene spent most of its life as a little-known Canadian biotechnology platform before moving its headquarters to the Boston area and reverse-merging onto public markets in 2023. The company's core technology relies on a carbohydrate polymer — chitosan — to deliver DNA plasmids directly to mucosal epithelial cells without the immunogenicity risks of viral vectors. This structural choice sets it apart from the AAV and lentiviral approaches that dominate gene therapy. enGene's sole clinical program, detalimogene voraplasmid, targets non-muscle invasive bladder cancer (NMIBC) in patients who have failed Bacillus Calmette-Guérin (BCG) therapy. The therapy is administered directly into the bladder via a catheter, where it transfects urothelial cells to produce a sustained immunostimulatory response. The pivotal Phase 2 LEGEND study completed enrollment in 2024, with data expected to support a Biologics License Application with the FDA. The company holds worldwide rights to its DDX platform and has generated early-stage data in cystic fibrosis and inflammatory bowel disease, though resources remain concentrated on the bladder cancer program. As of the first quarter of 2026, the company reported approximately $240 million in cash and equivalents, following a PIPE financing alongside its de-SPAC transaction and subsequent equity raises. The management team is led by CEO Jason Hanson, a former Medtronic and Covidien executive who joined in 2021, and Chief Scientific Officer James Sullivan, who has overseen the platform since its early days. The company's board includes representatives from Forbion and other venture investors who backed the private entity. No adjacent philanthropic or operating vehicles are publicly disclosed. enGene's structural differentiator is its non-viral delivery mechanism in a gene therapy field overwhelmingly reliant on viral vectors. By using a polymer that can be manufactured as a lyophilized powder and reconstituted at the point of care, the company avoids cold-chain logistics and the complex manufacturing burdens that have constrained the broader gene therapy sector. This utility-like formulation is uncommon in oncology gene therapy — most competitors rely on adenoviral or modified vaccinia platforms that face reproducibility and supply-chain bottlenecks.